Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLim, Hui Yin-
dc.contributor.authorPatel, Sheila K-
dc.contributor.authorHuang, Ping-
dc.contributor.authorTacey, Mark A-
dc.contributor.authorChoy, Kay Weng-
dc.contributor.authorWang, Julie-
dc.contributor.authorDonnan, Geoffrey A-
dc.contributor.authorNandurkar, Harshal H-
dc.contributor.authorHo, Prahlad-
dc.contributor.authorBurrell, Louise M-
dc.identifier.citationJournal of Personalized medicine 2022; 12(9)en
dc.description.abstractAngiotensin converting enzyme 2 (ACE2) is an endogenous negative regulator of the renin-angiotensin system, a key factor in the development of cardiovascular disease (CVD). ACE2 is also used by SARS-CoV-2 for host cell entry. Given that COVID-19 is associated with hypercoagulability, it is timely to explore the potential relationship between plasma ACE2 activity and the coagulation profile. In this cross-sectional study, ACE2 activity and global coagulation assays (GCA) including thromboelastography, thrombin, and fibrin generation were measured in adult healthy controls (n = 123; mean age 41 ± 17 years; 35% male) and in patients with cardiovascular risk factors and/or disease (n = 258; mean age 65 ± 14 years; 55% male). ACE2 activity was significantly lower in controls compared to patients with cardiovascular risk factors and/or disease (median 0.10 (0.02, 3.33) vs. 5.99 (1.95, 10.37) pmol/mL/min, p < 0.001). Of the healthy controls, 48% had undetectable ACE2 activity. Controls with detectable ACE2 had lower maximum amplitude (p < 0.001). In patients with cardiovascular risk factors and/or disease, those in the 3rd tertile were older and male (p = 0.002), with a higher Framingham grade and increased number of cardiovascular risk factors (p < 0.001). In conclusion, plasma ACE2 activity is undetectable to very low in young healthy controls with minimal clinically relevant associations to GCA. Patients with cardiovascular risk factors and/or disease have increased plasma ACE2 activity, suggesting that it may be an important biomarker of endothelial dysfunction and atherosclerosis.en
dc.subjectangiotensin converting enzyme 2en
dc.subjectcardiovascular diseaseen
dc.subjectrenin angiotensin systemen
dc.titlePlasma Angiotensin Converting Enzyme 2 (ACE2) Activity in Healthy Controls and Patients with Cardiovascular Risk Factors and/or Disease.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Personalized Medicineen
dc.identifier.affiliationThe Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC 3052,Australiaen
dc.identifier.affiliationNorthern Pathology Victoria, Northern Health, Epping, Melbourne, VIC 3076,Australiaen
dc.identifier.affiliationDepartment of Medicine, Northern Health, University of Melbourne, Epping, Melbourne, VIC 3076,Australiaen
dc.identifier.affiliationGeneral Medicineen
dc.identifier.affiliationAustralian Centre for Blood Diseases, Monash University, Melbourne VIC 3004,Australiaen
dc.identifier.affiliationThe Northern Hospital, Epping, VIC 3076,Australiaen
dc.identifier.affiliationDepartment of Medicine & Radiology, University of Melbourne, Parkville, VIC 3052,Australiaen
dc.identifier.pubmedid36143280, Louise M
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone- (University of Melbourne)- Oncology- Newton-John Cancer Wellness and Research Centre- Florey Institute of Neuroscience and Mental Health- Medicine- (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Sep 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.